このエントリーをはてなブックマークに追加
ID 55305
JaLCDOI
フルテキストURL
著者
Naganuma, Atsushi Department of Gastroenterology, Takasaki General Medical Center, National Hospital Organization
Hoshino, Takashi Department of Gastroenterology, Takasaki General Medical Center, National Hospital Organization
Suzuki, Yuhei Department of Gastroenterology, Takasaki General Medical Center, National Hospital Organization
Uehara, Daisuke Department of Gastroenterology, Takasaki General Medical Center, National Hospital Organization
Kudo, Tomohiro Department of Gastroenterology, Takasaki General Medical Center, National Hospital Organization
Ishihara, Hiroshi Department of Gastroenterology, Takasaki General Medical Center, National Hospital Organization
Sato, Ken Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine
Kakizaki, Satoru Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine
Yamada, Masanobu Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine
Takagi, Hitoshi Department of Gastroenterology, Kusunoki Hospital
抄録
The effect of skeletal muscle mass (SMM) on the outcomes of sorafenib treatment for hepatocellular carcinoma (HCC) has not been established. We measured the SMM in HCC patients treated with sorafenib, evaluated the patients’ survival, and evaluated the association between skeletal muscle depletion and sorafenib treatment. Of the 97 HCC patients treated with sorafenib at our institution in the period from July 2009 to February 2015, our study included 69 patients (51 males, 18 females) who had received sorafenib for ≥ 8 weeks and whose follow-up data were available. SMM was calculated from computed tomography images at the mid-L3 level (cm2) and normalized to height (m2) to yield the L3 skeletal muscle index (L3-SMI, cm2/m2). The median L3-SMI value was higher in the males (43 cm2/m2) compared to the females (36 cm2/m2). In the males only, the multivariate Cox regression identified an L3-SMI <43 cm2/m2 as independently associated with higher mortality compared to an L3-SMI ≥43 cm2/m2 (hazard ratio 2.315, 95% confidence interval: 1.125-4.765, p=0.023). Skeletal muscle depletion is a factor predicting poor prognosis for male patients with advanced HCC treated with sorafenib.
キーワード
skeletal muscle depletion
hepatocellular carcinoma
sorafenib
L3 skeletal muscle index
prognostic factor
Amo Type
Original Article
発行日
2017-08
出版物タイトル
Acta Medica Okayama
71巻
4号
出版者
Okayama University Medical School
開始ページ
291
終了ページ
299
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
English
著作権者
CopyrightⒸ 2017 by Okayama University Medical School
論文のバージョン
publisher
査読
有り
PubMed ID